Oncology Research Program

doi:10.6004/jnccn.2019.0046

Oncology Research Program

Volume/Issue:: Volume 17: Issue 9

Online Publication Date:: Sep 2019

DOI:: https://doi.org/10.6004/jnccn.2019.0046

Restricted access

All currencies in US Dollar

For more information on specific trials, including patient selection criteria, use the contact information listed with each study.

For more information on the NCCN ORP, including a complete detailing of the clinical studies currently underway at NCCN Member Institutions, go to www.NCCN.org/clinical_trials/clinicians.asp.

A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRα-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple-Negative Breast Cancer

Page Numbers:: xxvi

Article Category:: Other

Print Publication Date:: 01 Sep 2019

Online Publication Date:: Sep 2019

	All Time	Past Year	Past 30 Days
Abstract Views	0	0	0
Full Text Views	76	76	1
PDF Downloads	24	24	0
EPUB Downloads	0	0	0

Oncology Research Program

Article Sections

Article Information

PubMed

Google Scholar

Related Articles

Metrics